These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 4022211)

  • 1. Inhibition of platelet function by uremic middle molecules.
    Bazilinski N; Shaykh M; Dunea G; Mamdani B; Patel A; Czapek E; Ahmed S
    Nephron; 1985; 40(4):423-8. PubMed ID: 4022211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet function as an assay for uremic toxins.
    Lindsay RM; Dennis BN; Bergström JC; Jonsson C; Fürst P
    Artif Organs; 1981; 4 Suppl():82-9. PubMed ID: 7295101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effect of peak 2-4 of uremic middle molecules on platelet aggregation.
    Palés JL; López A; Asensio A; Merola E; Company X; Deulofeu R; Garcia M; Balagué A
    Eur J Haematol; 1987 Sep; 39(3):197-202. PubMed ID: 3678470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma phospholipids and platelet function in uremic patients.
    Vecino A; Teruel JL; Navarro JL; Cesar JM
    Am J Nephrol; 1996; 16(5):409-11. PubMed ID: 8886178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen.
    Di Minno G; Cerbone A; Usberti M; Cianciaruso B; Cortese A; Farace MJ; Martinez J; Murphy S
    J Lab Clin Med; 1986 Sep; 108(3):246-52. PubMed ID: 3018111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of alterations of uremic retention products upon platelet and peripheral nerve function.
    Lindsay RM; Bolton CF; Clark WF; Linton AL
    Clin Nephrol; 1983 Mar; 19(3):110-5. PubMed ID: 6839559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of platelet abnormalities in uremia with and without Glanzmann's thrombasthenia.
    Nomura S; Hamamoto K; Kawakatsu T; Kido H; Yamaguchi K; Fukuroi T; Suzuki M; Yanabu M; Shouzu A; Nishikawa M
    Nephron; 1994; 68(4):442-8. PubMed ID: 7870229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced platelet apoptosis in chronic uremic patients.
    Li M; Wang Z; Ma T; Lu G; Yan R; Zhao L; Deng K; Dai K
    Ren Fail; 2014 Jul; 36(6):847-53. PubMed ID: 24655051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "In vitro" inhibition of platelet aggregation by uremic middle molecules.
    Gallice P; Fournier N; Crevat A; Saingra S; Frayssinet R; Murisasco A; Sicardi F
    Biomedicine; 1980; 33(6):185-8. PubMed ID: 7213919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen fragments and platelet dysfunction in uremia.
    Kozek-Langenecker SA; Masaki T; Mohammad H; Green W; Mohammad SF; Cheung AK
    Kidney Int; 1999 Jul; 56(1):299-305. PubMed ID: 10411706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technical aspects on middle molecules: separation, isolation, and identification.
    Cueille G; Man NK; Sausse A; Farges JP; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():8-12. PubMed ID: 7295100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of endothelin-1 on aggregation of normal and uremic platelets.
    Pawlak K; Małyszko JS; Małyszko J; Myśliwiec M
    Pol J Pharmacol; 1996; 48(2):185-90. PubMed ID: 9112649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uremic toxins and the elusive middle molecules.
    Schoots A; Mikkers F; Cramers C; de Smet R; Ringoir S
    Nephron; 1984; 38(1):1-8. PubMed ID: 6472528
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
    Ringoir SM; van Landschoot N; de Smet R
    Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormalities of cytoplasmic Ca2+ in platelets from patients with uremia.
    Ware JA; Clark BA; Smith M; Salzman EW
    Blood; 1989 Jan; 73(1):172-6. PubMed ID: 2910357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uremic toxins inhibit the platelet malonyldialdehyde production rate.
    Tanaka H; Itoh S; Yamagami S; Kishimoto T; Maekawa M; Ringoir S
    Adv Exp Med Biol; 1987; 223():115-8. PubMed ID: 3447425
    [No Abstract]   [Full Text] [Related]  

  • 17. Analytical study for separation of middle molecules.
    Saito A; Kanazawa I; Chung TG; Maeda K
    Artif Organs; 1981; 4 Suppl():13-6. PubMed ID: 6975092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding time in uremia: a useful test to assess clinical bleeding.
    Steiner RW; Coggins C; Carvalho AC
    Am J Hematol; 1979; 7(2):107-17. PubMed ID: 539588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The beginning of repeated hemodialysis treatment enhances some platelet functions in uremic patients.
    Krawczyk W; Dmoszýnska A; Marczewski K
    Nephron; 1995; 71(3):361-2. PubMed ID: 8569990
    [No Abstract]   [Full Text] [Related]  

  • 20. [Study of middle molecules with positive reaction to ninhydrin present in uremic and normal blood and their isolation].
    Buzio C; Dall'Aglio PP; Delmonte G; Montagna G; Migone L
    Minerva Nefrol; 1979; 26(1):45-8. PubMed ID: 471320
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.